FDA Label Warning Threatens GSK's RSV Vaccine Sales -- Market Talk

Dow Jones

Jan 09, 2025

1122 GMT - The U.S. Food and Drug Administration's request for a label warning about Guillain-Barre syndrome risk on GSK's respiratory syncytial virus shot Arexvy could negatively impact vaccine sales, Bryan Garnier Research analysts say in a note. While a causal link between vaccination and GBS-- a rapid-onset muscle weakness caused by the immune system-- hasn't been proven, seven GBS cases per million Arexvy doses were observed, according to the FDA. "We believe the observed GBS incidence very close to natural GBS incidence in the non-vaccinated population," the analysts say. Arexvy sales already declined double-digit in 2H of 2024, following the narrowed recommendation to a smaller age range and more at-risk patients, the analysts say. Shares fall 0.04% at 1359.50 pence.(helena.smolak@wsj.com)

(END) Dow Jones Newswires

January 09, 2025 06:24 ET (11:24 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2502018810"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2502018810\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2502018810?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-09 19:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2502018810","market":"fut","top_or_hot":-1,"title":"FDA Label Warning Threatens GSK's RSV Vaccine Sales -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1122 GMT - The U.S. Food and Drug Administration's request for a label warning about Guillain-Barre syndrome risk on GSK's respiratory syncytial virus shot Arexvy could negatively impact vaccine sales, Bryan Garnier Research analysts say in a note. While a causal link between vaccination and GBS-- a rapid-onset muscle weakness caused by the immune system-- hasn't been proven, seven GBS cases per million Arexvy doses were observed, according to the FDA. \"We believe the observed GBS incidence very close to natural GBS incidence in the non-vaccinated population,\" the analysts say. Arexvy sales already declined double-digit in 2H of 2024, following the narrowed recommendation to a smaller age range and more at-risk patients, the analysts say. Shares fall 0.04% at 1359.50 pence.(helena.smolak@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 09, 2025 06:24 ET (11:24 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>FDA Label Warning Threatens GSK's RSV Vaccine Sales -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFDA Label Warning Threatens GSK's RSV Vaccine Sales -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-01-09 19:24</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     1122 GMT - The U.S. Food and Drug Administration's request for a label warning about Guillain-Barre syndrome risk on GSK's respiratory syncytial virus shot Arexvy could negatively impact vaccine sales, Bryan Garnier Research analysts say in a note. While a causal link between vaccination and GBS-- a rapid-onset muscle weakness caused by the immune system-- hasn't been proven, seven GBS cases per million Arexvy doses were observed, according to the FDA. \"We believe the observed GBS incidence very close to natural GBS incidence in the non-vaccinated population,\" the analysts say. Arexvy sales already declined double-digit in 2H of 2024, following the narrowed recommendation to a smaller age range and more at-risk patients, the analysts say. Shares fall 0.04% at 1359.50 pence.(helena.smolak@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 09, 2025 06:24 ET (11:24 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"GSK","symbol_name":"葛兰素史克","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2502018810","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2502018810","pubTimestamp":1736421840,"columns":[{"name":"Policy And Regulatory","id":32,"label_key":"policyRegulatory"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"1122 GMT - The U.S. Food and Drug Administration's request for a label warning about Guillain-Barre syndrome risk on GSK's respiratory syncytial virus shot Arexvy could negatively impact vaccine sales, Bryan Garnier Research analysts say in a note. While a causal link between vaccination and GBS-- a rapid-onset muscle weakness caused by the immune system-- hasn't been proven, seven GBS cases per million Arexvy doses were observed, according to the FDA. \"We believe the observed GBS incidence very close to natural GBS incidence in the non-vaccinated population,\" the analysts say. Arexvy sales already declined double-digit in 2H of 2024, following the narrowed recommendation to a smaller age range and more at-risk patients, the analysts say. Shares fall 0.04% at 1359.50 pence.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"GSK":"葛兰素史克"},"translate_title":"FDA标签警告威胁葛兰素史克RSV疫苗销售——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK":1},"content_text":"1122 GMT - The U.S. Food and Drug Administration's request for a label warning about Guillain-Barre syndrome risk on GSK's respiratory syncytial virus shot Arexvy could negatively impact vaccine sales, Bryan Garnier Research analysts say in a note. While a causal link between vaccination and GBS-- a rapid-onset muscle weakness caused by the immune system-- hasn't been proven, seven GBS cases per million Arexvy doses were observed, according to the FDA. \"We believe the observed GBS incidence very close to natural GBS incidence in the non-vaccinated population,\" the analysts say. Arexvy sales already declined double-digit in 2H of 2024, following the narrowed recommendation to a smaller age range and more at-risk patients, the analysts say. Shares fall 0.04% at 1359.50 pence.(helena.smolak@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 09, 2025 06:24 ET (11:24 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}